|
| 37424145 | Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy. | Prostate | 2023 |
| 37582240 | Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2023 |
| 37608258 | Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4Â weeks versus 2Â weeks (SHORTER). | BMC Cancer | 2023 |
| 37353441 | A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer. | Eur Urol | 2023 |
| 34364796 | A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. | Clin Genitourin Cancer | 2022 |
| 35728020 | Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. | J Clin Oncol | 2022 |
| 36104138 | Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial. | BMJ Open | 2022 |
| 35046520 | Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. | Br J Cancer | 2022 |
| 35231161 | The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. | Mol Oncol | 2022 |
| 34784056 | Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. | Cancer | 2022 |
| 33465252 | Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer. | Prostate | 2021 |
| 33765337 | Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). | Cancer | 2021 |
| 33680970 | Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. | Front Oncol | 2021 |
| 33867192 | A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. | Eur Urol | 2021 |
| 34859142 | From mouse genetics to targeting the Rag GTPase pathway. | Mol Cell Oncol | 2021 |
| 34286887 | Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. | Oncologist | 2021 |
| 34260908 | Inhibition of Rag GTPase signaling in mice suppresses B cell responses and lymphomagenesis with minimal detrimental trade-offs. | Cell Rep | 2021 |
| 34135321 | Limited survival and impaired hepatic fasting metabolism in mice with constitutive Rag GTPase signaling. | Nat Commun | 2021 |
| 32641261 | Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. | Clin Genitourin Cancer | 2020 |
| 31898184 | NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma. | Invest New Drugs | 2020 |
| 31865180 | Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma. | Transl Oncol | 2020 |
| 33273457 | Common germline-somatic variant interactions in advanced urothelial cancer. | Nat Commun | 2020 |
| 32975815 | Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. | Cancer | 2020 |
| 32718906 | Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. | Clin Genitourin Cancer | 2020 |
| 32600929 | Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup>Lu-J591) for metastatic castration-resistant prostate cancer. | Urol Oncol | 2020 |
| 32986533 | Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. | JCO Oncol Pract | 2020 |
| 31012963 | Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup> Lu-J591) for metastatic castration-resistant prostate cancer. | Cancer | 2019 |
| 31815952 | Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series. | PLoS One | 2019 |
| 31525487 | Clinical features of neuroendocrine prostate cancer. | Eur J Cancer | 2019 |
| 31579886 | Oncogenic Rag GTPase signaling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR. | Nat Metab | 2019 |
| 31278255 | Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. | Nat Commun | 2019 |
| 31592503 | Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. | JCO Precis Oncol | 2019 |
| 30865916 | Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. | J Natl Compr Canc Netw | 2019 |
| 29198585 | A multidisciplinary approach for the management of earlier stage renal cell carcinoma. | Urol Oncol | 2018 |
| 29848572 | Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. | Clin Cancer Res | 2018 |
| 29547835 | Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. | Eur J Cancer | 2018 |
| 27733359 | CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. | Cancer Discov | 2017 |
| 28379379 | PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far? | Ann Oncol | 2017 |
| 29333526 | Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. | JCO Precis Oncol | 2017 |
| 28720391 | Recommendations for the Management of Rare Kidney Cancers. | Eur Urol | 2017 |
| 26771706 | Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma. | J Clin Endocrinol Metab | 2016 |
| 26576779 | First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. | Cancer Chemother Pharmacol | 2016 |
| 27601542 | Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. | J Clin Oncol | 2016 |
| 27749842 | Clonal evolution of chemotherapy-resistant urothelial carcinoma. | Nat Genet | 2016 |
| 27528717 | Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival? | J Clin Oncol | 2016 |
| 27286790 | A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. | Oncologist | 2016 |
| 26780512 | PTEN recruitment controls synaptic and cognitive function in Alzheimer's models. | Nat Neurosci | 2016 |
| 27019698 | Recent advances in the management of renal cell carcinoma. | F1000Res | 2016 |
| 25023939 | Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis. | Clin Genitourin Cancer | 2015 |
| 26482279 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. | Lancet Oncol | 2015 |